ReviewImmunology2010
MHC class II epitope predictive algorithms.
Review in Immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
133 citing papers in PubMed, 2 syntheses or guidelines pooled it, 242 citations in OpenAlex.
- Opportunities and challenges with artificial intelligence in allergy and immunology: a bibliometric study.Frontiers in medicine · 2025Pooled it
- Challenges targeting cancer neoantigens in 2021: a systematic literature review.Expert review of vaccines · 2021Pooled it
- Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial.PLoS computational biology · 2015Trial
- Review
- Development and Immunogenicity Assessment of a Multi-Epitope Antigen Against Zika Virus: An In Silico and In Vivo Approach.Vaccines · 2025Article
- Novel bioinformatics approaches to design epitope-based vaccine against HIV latency by inquiring CTL epitopes and built-in adjuvants.Scientific reports · 2025Article
- Evaluation of Multipeptide Sequences Identified in Silico for the Serological Detection of Antibodies against Vector-Borne Diseases.The American journal of tropical medicine and hygiene · 2025Article
- Comparative performance analysis of neoepitope prediction algorithms in head and neck cancer.Frontiers in immunology · 2025Article
- An integrated immunoinformatic approach to design a novel multiepitope chimeric vaccine againstFrontiers in immunology · 2025Article
- Bioinformatics analysis to design a multi-epitope mRNA vaccine against S. agalactiae exploiting pathogenic proteins.Scientific reports · 2024Article
- Non-RBD peptides of SARS-CoV-2 spike protein exhibit immunodominance as they elicit both innate and adaptive immune responses.Heliyon · 2024Article
- Energy landscapes of peptide-MHC binding.PLoS computational biology · 2024Article
- Allogeneic HLA Humoral Immunogenicity and the Prediction of Donor-Specific HLA Antibody Development.Antibodies (Basel, Switzerland) · 2024Review
- Subtractive Proteomics and Reverse-Vaccinology Approaches for Novel Drug Target Identification and Chimeric Vaccine Development againstBioengineering (Basel, Switzerland) · 2024Article
- Structure-aware deep model for MHC-II peptide binding affinity prediction.BMC genomics · 2024Article
- Selection of vaccine-candidate peptides fromFrontiers in immunology · 2024Article
- Article
- Machine learning reveals limited contribution of trans-only encoded variants to the HLA-DQ immunopeptidome.Communications biology · 2023Article
- Bioinformatics analysis of structural protein to approach a vaccine candidate against Vibrio cholerae infection.Immunogenetics · 2023Article
- Designing a Next-Generation Multiepitope-Based Vaccine againstPathogens (Basel, Switzerland) · 2023Article
73 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
summaryMajor histocompatibility complex class II (MHC-II) molecules sample peptides from the extracellular space, allowing the immune system to detect the presence of foreign microbes from this compartment. To be able to predict the immune response to given pathogens, a number of methods have been developed to predict peptide-MHC binding. However, few methods other than the pioneering TEPITOPE/ProPred method have been developed for MHC-II. Despite recent progress in method development, the predictive performance for MHC-II remains significantly lower than what can be obtained for MHC-I. One reason for this is that the MHC-II molecule is open at both ends allowing binding of peptides extending out of the groove. The binding core of MHC-II-bound peptides is therefore not known a priori and the binding motif is hence not readily discernible. Recent progress has been obtained by including the flanking residues in the predictions. All attempts to make ab initio predictions based on protein structure have failed to reach predictive performances similar to those that can be obtained by data-driven methods. Thousands of different MHC-II alleles exist in humans. Recently developed pan-specific methods have been able to make reasonably accurate predictions for alleles that were not included in the training data. These methods can be used to define supertypes (clusters) of MHC-II alleles where alleles within each supertype have similar binding specificities. Furthermore, the pan-specific methods have been used to make a graphical atlas such as the MHCMotifviewer, which allows for visual comparison of specificities of different alleles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.